Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)
Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Pulmonary sarcoidosis patients with fibrosis often develop recurrent episodes of bronchitis.
These can lead to worsening of disease for both the short and long term.
Roflumilast has been shown to reduce the number of acute bronchitis episodes in patients with
COPD.
Drugs similar to Roflumilast have been shown to help sarcoidosis. The current study is to
determine if Roflumilast will reduce number of episodes of bronchitis and help fibrotic
sarcoidosis.
Phase:
Phase 4
Details
Lead Sponsor:
University of Cincinnati
Collaborators:
Albany Medical College Henry Ford Health System The Cleveland Clinic University of Illinois at Chicago University of Pittsburgh